Liposarcoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A usually painless malignant tumor that arises from adipose tissue. Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes. Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma. The metastatic potential is higher in less differentiated tumors.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Liposarcoma
- Therapeutic area
- Oncology
- liposarcoma
- lip sarcoma
- liposarcoma
- liposarcoma, malignant
- sarcoma of lip
- Severity
- Terminal
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0005060
- Parent condition
- MONDO:0002813
Related records
Broader conditions (18)
- Cancer
- Cancer or benign tumor
- Connective and soft tissue neoplasm
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Human disease
- Lipomatous cancer
- Malignant soft tissue neoplasm
- Mesenchymal cell neoplasm
- Neoplasm
- Neoplastic disease or syndrome
- Sarcoma
- Soft tissue neoplasm
- Soft tissue sarcoma
- Tumor of adipose tissue
Narrower conditions (25)
- Adult liposarcoma
- Breast liposarcoma
- Cutaneous liposarcoma
- Dedifferentiated liposarcoma
- Esophagus liposarcoma
- Fibroblastic liposarcoma
- Gastric liposarcoma
- Inflammatory liposarcoma
- Intracranial liposarcoma
- Kidney liposarcoma
- Larynx liposarcoma
- Liposarcoma of bone
- Liposarcoma of the ovary
- Mediastinum liposarcoma
- Mixed liposarcoma
- Myxoid liposarcoma
- Myxoid/round cell liposarcoma
- Ovarian myxoid liposarcoma
- Pediatric liposarcoma
- Pleomorphic liposarcoma
Trials (159)
- A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
- A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
- A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
- A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
- A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
- A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
- A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
- A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma
- A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma
- A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma
- A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
- A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
- A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
- A Study of Pembrolizumab in People With Ultra-Rare Sarcomas
- A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
- A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma
- A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma
- Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
- Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Approved drugs (2)
- Eribulin mesylate
- Trabectedin
Drugs in development (19)
- Alrizomadlin Phase 1
- Atirmociclib Phase 1
- Azacitidine Phase 1
- Bevacizumab Phase 2
- BTX-A51 Phase 1
- Doxorubicin Phase 2
- Efatutazone Phase 2
- Ifosfamide Phase 3
- Milademetan Phase 3
- Palbociclib Phase 2
- Pazopanib Phase 2
- Regorafenib Phase 2
- Ribociclib Phase 2
- Ridaforolimus Phase 2
- Romidepsin Phase 1
- Selinexor Phase 2
- Siremadlin Phase 1
- Sitravatinib Phase 2
- Toripalimab Phase 1